MDS with PNH clone (3)
| About this case study | |
| Details: | MDS with PNH clone (3) |
| Flow cytometry | |
| Details of flow cytometry instrument | BD FACSCanto |
| Cell populations evaluated for PNH clones: | Granulocytes, monocytes, RBCs |
| Treatments received (if applicable): | Myelodysplastic syndrome (RA – WHO) |
| External control: | None |
| Antibodies/reagents and gating strategies used: | FLAER-Alexa 488, CD14 (61D3)-PE, CD15 (H198)-APC, CD24 (SN3)-PE, CD64 (10.1)-PE, CD45 (2D1)-PerCP-Cy5.5, CD59 (MEM43)-PE, CD235a (KC16)-FITC Practical Guidelines 2012 |
| Clone sizes in all populations tested: | Granulocytes: 44.6% (Type II + III) |
| LDH level: | 19.8 µkat/L (2.2–3.6) |
| RBC count: | 3.54 x 1012/L (4.70–6.10) |
| WBC and neutrophil counts: | 5.3 x 109/L (4.00–10.80) |
| Platelet count: | 120.00 x 109/L (150.00–400.00) |
FLAER, fluorescent aerolysin; LDH, lactate dehydrogenase; MDS, myelodysplastic syndrome; RA, refractory anaemia; RBC, red blood cell; WBC, white blood cell; WHO, World Health Organization
FC data
Dot plots
